Brain Neoplasms
Conditions
Brief summary
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.
Interventions
DIAGNOSTIC_TESTNovel Gadolinium-Weighted MRI Sequence
A post-contrast MRI sequence incorporating magnetization transfer (MT) preparation and flow-nulling with motion-sensitized driven equilibrium (MSDE). The sequence is optimized to suppress background tissue and vascular signal while enhancing the visibility of gadolinium-enhancing brain metastases. It is compared to conventional T1-weighted imaging in the same exam session.
Sponsors
Region Stockholm
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older * Scheduled for clinical brain MRI with gadolinium contrast * Known or suspected brain metastases * Able to provide informed consent * Able to lie still for the duration of the MRI examination
Exclusion criteria
* Contraindications to MRI * Known allergy or contraindication to gadolinium-based contrast agents * Renal impairment (eGFR \< 30 mL/min/1.73m²) * Pregnant or breastfeeding * Inability to comply with study procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in Number of Detected Gadolinium-Enhancing Brain Metastases Between the Novel Gadolinium-Weighted MRI Sequence and Conventional T1-Weighted Imaging | At the time of gadolinium-enhanced MRI, during a single imaging session (within 1 hour of contrast administration) |
Countries
Sweden
Outcome results
None listed